Quality of life (QOL) can be significantly impacted by symptoms of overactive bladder (OAB). Vibegron is a highly selective β3 -adernergic receptor agonist that showed efficacy in treatment of symptoms of OAB in the randomized, double-blind, placebo- and active-controlled phase 3 EMPOWUR trial.